Prothena reported $-72000 in Operating Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US USD -46063000 15.2M
Agios Pharmaceuticals AGIO:US USD 28.68M 115.33M
Akebia Therapeutics AKBA:US USD -6350000 42.73M
ALKERMES ALKS:US USD -20582000 40.06M
Alnylam Pharmaceuticals ALNY:US USD -188614000 146.01M
Amgen AMGN:US USD 2.23B 508M
Biogen BIIB:US USD 699.9M 615.2M
Biomarin Pharmaceutical BMRN:US USD -24500000 22.08M
Bluebird Bio BLUE:US USD -84781000 22.62M
Exelixis EXEL:US USD -48078000 130.69M
Intercept Pharmaceuticals ICPT:US USD -18024000 83.88M
Intra Cellular Therapies ITCI:US USD -47412000 8.22M
Macrogenics MGNX:US USD 11.98M 36.94M
Nektar Therapeutics NKTR:US USD -52469000 1.83M
Neurocrine Biosciences NBIX:US USD 103.4M 15.6M
Prothena PRTA:US USD -72000 50.26M
Regeneron Pharmaceuticals REGN:US USD 1.15B 76.9M
Seattle Genetics SGEN:US USD -154004000 38.8M
Ultragenyx Pharmaceutical RARE:US USD -145628000 79.44M
Vertex Pharmaceuticals VRTX:US USD 1.03B 93.2M
Vital Therapies VTL:US USD -57327000 37.21M
Xoma XOMA:US USD -6210000 1.84M
YTE INCY:US USD 70.09M 68.28M